Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerenis Therapeutics SA

www.cerenis.com

Latest From Cerenis Therapeutics SA

Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates

In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.

Deals Intellectual Property

Pipeline Watch: Phase III Data For Abemaciclib, JZP-110 And NKTR-181

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

What To Look Out For At ACC

Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting.

Cardiovascular Clinical Trials

Pipeline Watch: Phase III Starts With Plinabulin, Rova-T And Relugolix

Pipeline Watch is Scrip's weekly update on the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Cerenis Therapeutics SA
  • Senior Management
  • Jean-Louis Dasseux, PhD, Pres. & CEO
    Cyrille Tupin, Dir., Fin.
    Tom Brya, SVP, Bus. Dev.
    Renee Benghozi, MD, CMO
  • Contact Info
  • Cerenis Therapeutics SA
    Phone: (33) 5 62 24 97 06
    265 rue de la Découverte - Bât. A
    Labege, 31670
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register